Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK.
Authors
Califano, RaffaeleTariq, Noor-Ul-Ain
Compton, S
Fitzgerald, D
Harwood, C
Lal, R
Lester, J
McPhelim, J
Mulatero, C
Subramanian, S
Thomas, A
Thatcher, Nick
Nicolson, M
Affiliation
Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BXIssue Date
2015-07-18
Metadata
Show full item recordAbstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying progression and improvement of quality of life over palliative platinum-based chemotherapy. The most common adverse events (AEs) are gastrointestinal (GI) (diarrhoea and stomatitis/mucositis) and cutaneous (rash, dry skin and paronychia). These are usually mild, but if they become moderate or severe, they can have a negative impact on the patient's quality of life (QOL) and lead to dose modifications or drug discontinuation. Appropriate management of AEs, including prophylactic measures, supportive medications, treatment delays and dose reductions, is essential. A consensus meeting of a UK-based multidisciplinary panel composed of medical and clinical oncologists with a special interest in lung cancer, dermatologists, gastroenterologists, lung cancer nurse specialists and oncology pharmacists was held to develop guidelines on prevention and management of cutaneous (rash, dry skin and paronychia) and GI (diarrhoea, stomatitis and mucositis) AEs associated with the administration of EGFR-TKIs. These guidelines detail supportive measures, treatment delays and dose reductions for EGFR-TKIs. Although the focus of the guidelines is to support healthcare professionals in UK clinical practice, it is anticipated that the management strategies proposed will also be applicable in non-UK settings.Citation
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. 2015: DrugsJournal
DrugsDOI
10.1007/s40265-015-0434-6PubMed ID
26187773Type
ArticleLanguage
enISSN
0012-6667ae974a485f413a2113503eed53cd6c53
10.1007/s40265-015-0434-6
Scopus Count
Collections
Related articles
- First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
- Authors: Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA
- Issue date: 2021 Mar 18
- First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
- Authors: Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA
- Issue date: 2016 May 25
- A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
- Authors: Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, Mori M, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A
- Issue date: 2021 Mar 1
- Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.
- Authors: Occhipinti M, Imbimbo M, Ferrara R, Simeon V, Fiscon G, Marchal C, Skoetz N, Viscardi G
- Issue date: 2025 May 27
- [EGFR-TKI ADR Management Chinese Expert Consensus].
- Authors: Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
- Issue date: 2019 Feb 20